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CD56 and CD30 in lymphomas
Cutaneous lymphomas derived from natural killer
(NK) or NK-like T-cells are rare among hematolym-
phoid malignancies presenting in the skin.1–6 We have
recently reported a series of 12 patients with cu-
taneous presentation of NK and NK-like T-cell lym-
phomas that demonstrate a dense superficial and
deep dermal lymphoid infiltrate often with an angi-
ocentric growth pattern and a characteristic immuno-
phenotype (CD56π, CD43π, TCRgª, CD3ª/π,
CD20ª, CD4ª, CD8ª).7 These lymphomas showed
aggressive behavior with a median survival of 15
months from the time of diagnosis. In addition, one
of the 12 cases displayed immunoreactivity of the
CD56π atypical large cells for CD30, a member of
the nerve growth factor receptor superfamily ex-
pressed in activated T and B cells, Hodgkin’s disease
and anaplastic large cell lymphoma.8–11
Cutaneous lymphoproliferative disorders express-
ing the CD30 antigen form a heterogeneous spectrum
which encompasses lymphomatoid papulosis (LyP),
some examples of tumor stage mycosis fungoides and
several lymphomas with and without anaplastic cy-
tology.11–18 Secondary cutaneous anaplastic large cell
lymphoma (ALCL) and ALCL arising in mycosis
fungoides have a poor prognosis, but primary cu-
taneous CD30π ALCLs are associated with a good
prognosis with an overall survival rate estimated to be
greater than 90% at 5 years.13–19 NK and NK-like
T-cell lymphomas involving the skin usually have a
poor prognosis. While the biologic behavior of NK
and NK-like T-cell lymphomas presenting in the skin
and ALCLs are widely disparate, the initial clinical
presentation as well as the histologic features can dis-
play significant overlap and may pose considerable
diagnostic difficulty. Cutaneous lymphomas that co-
express CD56 and CD30 appear to be rare.4,6,20–25
The biological significance of this co-expression is as
yet unclear.
We undertook the current study to characterize the
clinical, morphologic, immunophenotypic and mol-
ecular features of lymphomas presenting in the skin
that co-express CD56 and CD30. In addition, we
have tested for the presence of the Epstein-Barr virus
Table 1. Antibody reagents used for immunohistochemical studies
Antigen Antibody/clone Source Cell reactivity
CD3 Polyclonal CD3 Dako, Carpinteria, CA, USA T cells
CD4 IF6 Novocastra, UK T helper/inducer, monocytes
CD8 C8/144B Dako T cytotoxic/suppressor
CD20 L26 Dako B cells
CD30 BerH2 Dako Activated T and B cells
CD43 Leu22 Becton Dickinson, San Jose, CA, USA T cells, other
CD56 123C3 Monosan, Uden, The Netherlands NK, NK-like T cells
CD68 KP1 Dako Myeloid, macrophage
TIA-1 NS/1-AG4 Coulter, Hialeah, FL, USA NK, T cytotoxic
MPO Myeloperoxidase Dako Myeloid lineage
Ki-67 MIB-1 Immunotech, Cedex, France Proliferating cells
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(EBV), which is variably associated with both ALCL
and NK and NK-like T-cell malignancies.3,4,6,7,20,26
Material and methods
Case selection
A review of Stanford surgical pathology records from
1995–1998 yielded 52 cases of cutaneous lympho-
proliferative disorders with reactivity for CD30.
Immunostains for CD56 were performed on these
cases as described below. All cases of NK and NK-
like T-cell lymphomas had been previously tested for
CD30.7 In addition, 10 cases of ALCL seen at the
University of Michigan (Ann Arbor, MI, USA) were
also stained for CD56. From these cases, seven lym-
phomas that co-express CD56 and CD30 with pres-
entation of disease in the skin were selected. Histo-
logic sections and immunohistochemical studies per-
formed at the time of diagnosis were reviewed. The
staging evaluation at the time of diagnosis included
complete blood count and chemistries, chest X-ray or
chest computed tomography (CT), CT of abdomen
and pelvis, and bone marrow biopsy.
Histologic features
Hematoxylin and eosin (H&E)-stained sections were
reviewed to assess histologic parameters including epi-
dermotropism, angiocentrism, angiodestruction, fat
involvement, ulceration, necrosis, anaplasia, promi-
nence of nucleoli, and karyorrhexis. These par-
ameters were categorized as absent/inconspicuous
(ª), mild (π), or prominent (ππ).
Immunohistochemistry
Primary antibodies were directed against CD3,
CD4, CD8, CD20, CD30, CD43, CD56, CD68,
TIA1, MPO (myeloperoxidase) and Ki-67 (summar-
ized in Table 1). Serial sections of 4 microns were
cut and deparaffinized in xylene and hydrated in a
graded series of alcohol. The sections were then
pretreated by a microwave procedure in citric acid
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buffer (10 mM, pH 6.0) for 10 min prior to staining
for CD3, CD8, CD20, CD30, CD43, CD56,
CD68, TIA-1, and Ki-67. For CD4, pretreatment
was performed in EDTA (1mM, pH 8.0). Endoge-
nous peroxidase was blocked by preincubation with
1% hydrogen peroxide in phosphate-buffered saline.
Detection for CD3, CD20, CD30, CD43, CD68,
MPO and TIA-1 was performed on an automated
staining machine (Ventana Medical Systems Inc.,
Tucson, AZ, USA). Detection for CD56, Ki-67,
and CD4 was performed using a modified biotin-
streptavidin method.27
In situ hybridization for EBV
EBV RNA in situ hybridization studies were per-
formed using a 30-base oligonucleotide probe com-
plementary to a portion of the EBER1 gene as pre-
viously described.28 Five-micron thick paraffin sec-
tions were deparaffinized, rehydrated, predigested
with proteinase K and hybridized overnight at a con-
centration of 0.25 ng/ml of biotinylated probe. De-
tection was accomplished using avidin-alkaline phos-
phatase conjugate. Appropriate positive and negative
controls were performed.
Heteroduplex analysis of T-cell receptor gamma (TCR-g)
gene rearrangement
Amplification and heteroduplex analysis for TCR-g
gene rearrangement was performed as previously de-
scribed.29 Consensus primers for the TCR V-J junc-
tion were used to amplify genomic DNA isolated from
paraffin-embedded tissue as described.29 The ampli-
fied products were then analyzed on a Mutation De-
tection Enhancement (MDE) gel (FMC Bioproducts,
Rocklands, ME, USA) for 12 h at 90 V in tris-borate-
EDTA buffer.
Table 2. Clinical summary
Case Age/sex Presenting signs and symptoms Documented sites Treatment Outcome
of involvement (MΩmonths)
1 43/F Single polypoid nodule on left hip Skin Chemotherapy and local radiation AIR, 9 M
2 19/M Tumor nodules on abdomen, trunk and Skin Chemotherapy and total skin radiation AIR, 20 M
upper extremity; recurrence on trunk and with autologous bone marrow transplant
extremities
3 79/F Tumor nodules on calf and ankle; recurrence Skin Local radiation AIR, 18 M
on thigh
4 52/M Single multinodular plaque on upper Skin Chemotherapy; local radiation for recurrence AIR, 30 M
extremity; recurrence, same area
5 50/F Single nodule on great toe Skin Observation AIR, 24 M
6 37/M Ulcerating nodules on extremities, trunk, Skin, soft palate Local radiation; Chemotherapy for DOD, 15 M
and scrotum; recurrence on trunk, lower recurrence
extremity, and soft palate
7 47/M Multiple tumor nodules on posterior Skin Observation; recurrent lesions are AWD, 15 M
right leg self-resolving




The clinical findings are summarized in Table 2. The
patients included four men and three women ranging
in age from 19 to 79 years (mean age 46.7 years). All
patients presented with initial manifestation of
lymphoma in the skin. Six patients had disease con-
fined to the skin as assessed by a staging workup. One
patient (case 6) developed involvement of the soft pal-
ate 6 months after the initial skin diagnosis. None
of the patients had lymph node or peripheral blood
involvement. Four of the seven patients had multiple
skin lesions at presentation, while three had disease
limited to a single cutaneous lesion. The initial cu-
taneous lesions were found on the upper and/or
lower extremities in four patients, confined to the hip
in one patient and involved the trunk in addition to
the extremities in the remaining two patients. None
of the patients had significant past medical histories,
evidence of immunosuppression or prior malig-
nancies.
The disease course was variable in the seven pa-
tients (Table 2). Four patients are in clinical remission
without relapse (cases 1, 2, 3, and 5), one patient is
in remission with history of relapse (case 4), one pa-
tient is alive with recurrent disease (case 7), and one
patient died of disease (case 6). Three patients were
initially treated with chemotherapy (case 1, 2 and 4)
of whom two, in addition, received local (case 1) or
total skin radiation (case 2). Patient 2 received an
autologous bone marrow transplantation after only
partial response to initial therapy, and is in clinical
remission at the time of completion of this study. Two
patients were treated initially with local radiation
alone (cases 3 and 6), one of whom remains in clinical
remission (case 3), while the other patient had recur-
rence involving the trunk, extremities and the soft pal-
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Table 3. Histologic features
Parameter 1 2 3 4 5 6 7
Epidermotropism π π π NA* ππ 0 0
Angiocentric infiltrate π ππ ππ ππ ππ ππ ππ
Angiodestruction 0 π ππ ππ π π 0
Panniculitis-like infiltrate 0 NA** ππ NA** π π π
Ulceration π π 0 π 0 ππ 0
Necrosis 0 0 π 0 0 π 0
Anaplasia ππ π π ππ π ππ π
Prominence of nucleoli 0 0 π 0 π 0 π
Karyorrhexis ππ π ππ ππ π ππ ππ
All histologic parameters were scored as follows:
Absent/inconspicuous (ª), mild (π), prominent (ππ), or not assessed (NA).
* no epidermis available for assessment of epidermotropism.
** depth of biopsy insufficient for evaluation of panniculitis-like infiltrate.
ate requiring chemotherapy and died of disease (case
6). Two patients received no treatment at all (cases 5
and 7). Patient 5 who presented with a single nodule
on the toe, underwent spontaneous resolution and is
without disease two years after diagnosis. The other
patient continues to have recurrent self-resolving nod-
ules (case 7).
Histologic features
The histologic findings are summarized in Table 3.
The skin biopsies from all seven patients exhibited
dense lymphoid infiltrates with atypical cytologic fea-
tures. These infiltrates had a ‘‘column-like’’ architec-
ture exemplified by extension of the infiltrates from
the superficial to the deep dermis with prominent
perivascular and periappendageal involvement. An
increased density of neoplastic cells was present deep
within the dermis (Fig. 1A).
Fig. 1. Skin biopsy. A) Atypical lymphoid infiltrate exhibiting col-
umn-like architecture and a dense infiltrate in the deep dermis (H&
E, ¿60). B) Neoplastic cells showing mild epidermotropism (H&E,
¿150). C) Large neoplastic cells with pleomorphic nuclear contours
admixed with small reactive lymphocytes with condensed chroma-
tin (H&E, ¿600). D) Neoplastic cells showing angiodestruction
(H&E, ¿600). E) Focus of necrosis within the dermis (H&E, ¿600).
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Epidermotropism was a minor component in four
of six cases, although in one case a prominent epider-
mal infiltrate was seen (case 5). Angiocentric infiltrates
were observed in all cases, while angiodestructive
lesions were present in five cases (Fig. 1B). Destruc-
tion of adnexal structures was not observed. Involve-
ment of the fat (panniculitis-like infiltration) was a
prominent finding in four of five cases where the
depth of the biopsy was adequate for assessment of
this parameter. Ulceration was present in three cases
(2, 4 and 6), while areas of necrosis within the dermis
were observed in two biopsies (cases 3 and 6).
The cytology of the lymphoid infiltrates revealed a
mixture of cell sizes ranging from small to medium to
large. In all biopsies, the medium- to large-sized cells
displayed nuclear pleomorphism; however, anaplastic
cytology was prominent in three cases (1, 4, and 6;
Fig. 1C). Marked karyorrhexis was present in five of
seven cases. Scattered small lymphoid cells and histio-
cytes were admixed with the large atypical cells, most
likely representing a host response. Occasional histio-
cytes and eosinophils were also present intermingled
with the atypical lymphoid cells.
Immunohistochemical studies
Results from immunohistochemical studies are sum-
marized in Table 4. Cutaneous biopsies from all seven
patients revealed immunoreactivity of the large atypi-
cal cells for CD56 and CD30 (Fig. 2A, B), as this was
a criterion for selection for the study. Staining for
both markers was predominantly localized to the cell
membranes. The number of atypical cells stained in
each case was variable, as indicated in Table 4. Six
of the seven cases displayed immunoreactivity with
polyclonal anti-CD3, which recognizes the epsilon (e)
subunit of the T-cell receptor-CD3 signal transduc-
tion complex (Fig. 2C). All cases showed strong im-
munoreactivity for CD43. The atypical cells from all
seven cases lacked staining for the T-helper/inducer
marker, CD4, T-cytotoxic/suppresser marker, CD8,
the B-cell marker CD20, myeloperoxidase (MPO)
Natkunam et al.
Table 4. Immunohistochemistry, in situ hybridization and molecular analyses
Antigen 1 2 3 4 5 6 7 Total
CD56 π20%* π.50% π.80% π.80% π.80%. π.80% π10% 7/7 (100%)
CD30 π.90% π.50% π.80% π.80% π20% π30% π.80% 7/7 (100%)
CD3 π π π π π ª π 6/7 (86%)
CD4 ª ª ª ª ª ª ª 0/7 (0%)
CD8 ª ª ª ª ª ª ª 0/7 (0%)
CD20 ª ª ª ª ª ª ª 0/7 (0%)
CD43 π π π π π π π 7/7 (100%)
CD68 ª ª ª ª ª ª ª 0/7 (0%)
TIA1 π ª π ª π ª ª 3/7 (42%)
MPO ª ª ª ª ª ª ª 0/7 (0%)
Ki-67 90% 30% 90% 30% 60% 30% 80% 30–90%
EBV in situ hybridization ª ª π π ª π ª 3/7 (42%)
PCR analysis for TCRg π π ª ª ª ª π 3/7 (42%)
*Percent of lesional cells positive for CD56 and CD30.
and the myeloid/macrophage-associated antigen,
CD68. A subset of small lymphoid cells showed posi-
tive staining for CD8 (Fig. 2D). These cells presum-
ably correspond to reactive T cells. Three of seven
cases showed staining for TIA-1 (Fig. 2E). All seven
cases showed moderate to high proliferation rates
(30–90%) as assessed by Ki-67, a nuclear antigen ex-
pressed in proliferating cells (Fig. 2F), corroborating
the histologic findings of often brisk mitotic activity
seen on hematoxylin and eosin (H&E)-stained sec-
tions.
In situ hybridization for EBV
Results of in situ hybridization studies are summarized
in Table 4. Using the EBER1 oligonucleotide probe,
three of seven cases exhibited nuclear localization of
EBV mRNA within atypical cells constituting the cu-
taneous lymphoid infiltrates.
Fig. 2. Immunohistochemical studies showing reactivity for CD56,
CD30, CD3, CD8, TIA-1 and Ki-67, by the neoplastic cells (H&
E, ¿600).
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Heteroduplex analyses of TCR-g gene rearrangement
Results of TCR-g rearrangement studies are summar-
ized in Table 4. Three cases showed strong clonal
bands indicating the presence of TCR-g gene re-
arrangements. As T-cell receptor gene rearrange-
ments would not be expected in lymphomas derived
from natural killer cells, these three lymphomas are
most likely derived from T cells.
Discussion
The seven patients described in this study are unusual
in that they had lymphomas exhibiting a rare
CD56π, CD30π immunophenotype with the initial
manifestation of their disease in the skin. There are a
few reports of lymphomas with co-expression of
CD56 and CD30.4,6,7,20,21,23–25 All of these reported
cases of lymphomas were localized to extranodal sites,
of which three presented with lymphoma in the
skin.7,25 These investigations suggest that co-express-
ion of CD56 and CD30, especially in lymphomas
with primary presentation in the skin, is exceedingly
rare.
The patients in the current study showed a wide
age distribution and no particular sex predilection.
The most common sites of involvement were the ex-
tremities and trunk, similar to previous reports of cu-
taneous NK and NK-like T-cell lymphomas,3,4,7 and
ALCL, although ALCL also commonly involves the
scalp and face.13,17 Similarly, single or multiple nod-
ules, often ulcerated were typical in these patients, as
reported in both diseases.3,4,7,13,17 Nuclear pleo-
morphism has been described in both NK and NK-
like T-cell lymphomas and ALCL; however, promi-
nent anaplastic cytology, a feature of three of the
cases in this study, is particularly distinctive of
ALCL.1–3,6,7,11,13,17,30 While two of the patients in
our study who displayed anaplastic cytology (cases 4
and 6) exhibited an aggressive clinical course, another
CD56 and CD30 in lymphomas
patient whose biopsy displayed marked anaplasia
(case 1), did not. Angiocentric distribution of the
atypical infiltrate, present in all cases in this study,
is commonly associated with NK and NK-like T-cell
lymphomas ALCL.1–3,6,7,30 This pattern of infiltration
is less frequent in ALCL.17 Infiltration and destruc-
tion of vessel walls, apparent in five of seven cases in
this study is most frequent in NK and NK-like T-cell
lymphomas.1–3,6,7,30 Thus, the histologic features of
these seven cases show significant overlap with those
of NK and NK-like T-cell lymphomas and ALCL.
By definition, all seven cases in our study showed
immunoreactivity for CD56 and CD30 in the large
atypical cells, although variable numbers of cells ex-
hibited positive staining for each of these markers.
The typical immunophenotype was as follows:
CD56π, CD30π, CD43π, CD3(e)π/ª, TIA1ª/
π, CD4ª, CD8ª, CD20ª, CD68ª, MPOª. Im-
munoreactivity for TIA-1, a cytoplasmic granule-as-
sociated protein found in cytotoxic T cells and NK
cells, was observed in three of seven cases (42%) in
our study. Other investigators have reported TIA-1
expression in 63–92% of ALCL and NK and NK-like
T-cell lymphomas.17,25,31–33 This immunophenotype
shows significant overlap between the immunopheno-
typic profiles reported for NK and NK-like T-cell
lymphomas and ALCL.
A very high correlation between NK and NK-like
T-cell lymphomas, especially of the nasal-type, and
EBV has been reported by some authors,3,5,26,34 while
an inconsistent association has been reported by
others.7,26 Occasional cases of ALCL are also known
to harbor EBV mRNA,35–38 although a vast majority
of ALCL cases lack EBV.17 In the current study, EBV
mRNA was detected in three of seven cases (42%),
utilizing in situ hybridization studies for EBER1
mRNA. There was no distinct correlation between
EBV mRNA expression and adverse clinical outcome
in our study.
Immunoreactivity for cytoplasmic CD3 (CD3 epsi-
lon), a component of the TCR signal transduction
complex, was detected in six cases, while clonal TCR-
g rearrangement confirming a T-cell lineage was de-
tected in only three cases. Thus, four of the cases in
this study may be of true NK-cell derivation, as clonal
rearrangement of TCR-g is a feature of T-cell lineage
while CD3e can be expressed by cells of pure NK
lineage. Immunohistochemical and molecular analy-
ses have demonstrated clonality in approximately
91% of CD30π ALCL.17,32,33 Thus, a minority of
cases of ALCL may not exhibit detectable TCR gene
rearrangements. The absence of TCR-g rearrange-
ments in four cases in our study does not differentiate
between a T-cell or an NK-cell derivation for these
lymphomas. A bipotential progenitor cell giving rise
to true NK lymphomas as well as NK-like T-cell lym-
phomas,39–41 may be a likely derivation for lym-
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phomas co-expressing CD56 and CD30, especially
for those with an adverse clinical course. However,
an activated CD30π T-cell with aberrant expression
of CD56,21 may also be responsible for lymphomag-
enesis. While determining the cell of origin may be
important for understanding the biological behavior
of these lymphomas and for classification, it is not
clear whether this is pertinent for diagnosis or man-
agement.
Cutaneous CD56π NK and NK-like T-cell lym-
phomas are highly aggressive and are often ac-
companied by treatment failure, multiple recurrences,
dissemination to other sites and poor clinical out-
come.1–4,6,7,30 In contrast, CD30πALCLs that are
limited to the skin at presentation as solitary or
multiple nodules are associated with an excellent
prognosis. Spontaneous regression with or without re-
lapse is observed in CD30π ALCLs and the five year
overall survival rate is estimated to be 90%.11,14–19
The disease course of patients in our study was vari-
able, and ranged from spontaneous resolution in one
patient, clinical remission post-treatment in four pa-
tients, alive with recurrent disease in one patient, and
death from disease with involvement of another
extranodal site (soft palate) in one patient. While one
of the patients (cases 6) had disease that behaved in
a more aggressive manner than primary cutaneous
CD30π ALCL, the other six patients displayed a
clinical course considered typical for primary cu-
taneous CD30π ALCL. It is unclear whether the less
aggressive clinical course in these latter six patients
is due to the biological behavior associated with co-
expression of CD56 and CD30 or to the limited in-
volvement of their disease mostly in one anatomical
location, or both. The rarity of primary cutaneous
lymphomas with co-expression of CD56 and CD30,
together with the relatively short follow-up period of
patients in our study, make assessment of prognosis
difficult. Further clinicopathologic investigations on
larger numbers of patients are needed for an accurate
and meaningful evaluation of prognosis in these lym-
phomas.
Our results indicate that cutaneous lymphomas
that co-express CD56 and CD30 share significant
clinicopathologic overlap with cutaneous ALCL and
NK and NK-like T-cell lymphomas. Immunopheno-
typic studies are imperative in distinguishing these
lymphomas from mycosis fungoides, lymphomatoid
papulosis, peripheral T-cell lymphoma, subcutaneous
panniculitic T-cell lymphoma,42 myeloid/natural
killer cell precursor lymphoma/leukemia,43–45 CD4π
CD56π cutaneous neoplasm,46 and cutaneous B-cell
lymphoma, which are considerations in the histologic
differential diagnosis. Thus, CD56 and CD30 are im-
portant markers in a panel selected for immunohistol-
ogic studies when evaluating a dense deep dermal
atypical lymphoid infiltrate, and both antigens should
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be assessed together. Predictions of prognosis based
on our data are difficult. Further investigations are
needed to characterize the mechanism of how a neu-
ral cell adhesion molecule such as CD56 and a
growth factor receptor-like molecule such as CD30
may orchestrate the pathogenesis and progression of
these rare lymphomas.
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